Peptide Sequence Optimization: Balancing Potency, Stability, and Manufacturability

Keep the tradeoffs visible

Changing a residue or terminus can affect target binding, proteolysis, solubility, aggregation, permeability, immunogenicity, and synthesis. Use a design register that records the hypothesis, exact modification, assay context, result, and next decision.

Research operations

Coordinators can register sequences, reconcile sample identifiers, maintain assay links, and preserve decision meetings. Chemists, biologists, and development leads own interpretation.

Measured finding and limit

In a 2024 machine-learning study of human GCGR and GLP-1R peptide variants, 3 model-designed sequences showed up to a 7 fold potency improvement at both receptors versus the best dual agonist in the training set. The result is an in-vitro, model-guided comparison; it does not establish improved exposure, safety, stability, or clinical benefit. A sequence register should therefore preserve the assay system, comparator, unit or fold-change, sample set, and property that was not measured.

Scope note

This brief is educational and does not recommend a sequence.

Make each analogue a measured comparison

The 2024 machine-learning study reported up to a 7-fold potency improvement for three model-designed human GCGR and GLP-1R peptide variants against the best dual agonist in its training set. This is an in-vitro, model-guided comparison: it names a fold-change and comparator, but does not measure exposure, proteolytic half-life, aggregation, immunogenicity, manufacturability, or clinical benefit. Those unmeasured properties belong in the decision record before a sequence is treated as optimized.

For each analogue, retain exact sequence and modification, assay system, concentration unit, replicate structure, comparator, potency endpoint, stability time and matrix, solubility, impurity profile, and synthesis yield. A coordinator can version the design register and reconcile sample identifiers across chemistry and biology. Scientists own the multi-objective interpretation; potency must not silently overwrite a stability loss or increase in deletion sequences.